Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 10, 2003, Pages 1623-1626

  Bargota, Rakesh S ^a   Akhtar, Mahmoud ^a   Biggadike, Keith ^b   Gani, David ^a   Allemann, Rudolf K ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; ARYLDIALKYLPHOSPHATASE; HYDROGEN; PARAOXON; PHENYLACETIC ACID;

ARTICLE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HYDROLYSIS; STRUCTURE ACTIVITY RELATION;

EID: 0037687922     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00290-7     Document Type: Article

References (39)

1. Gan K.N., Eckerson H.W., La Du B.N. Drug. Metab. Dispos. 19:1991;100.
2. Aldridge W.N. Biochem. J. 53:1953;117.
3. La Du B.N. Pharmacogenetics of Drug Metabolism. Kalow W. 1992;51 Pergamon, New York.
4. Mackness B., Durrington P.N., Mackness M.I. Gen. Pharmac. 31:1998;329.
5. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Curr. Opin. Lipidol. 7:1996;69.
6. Sogorb M.A., Vilanova E. Toxicol. Lett. 128:2002;215.
7. Biggadike K., Angell R.M., Burgess C.M., Farrel R.M., Hancock A.P., Harker A.J., Irving W.R., Ioannou C., Procopiou P.A., Shaw R.E., Solanke Y.E., Singh O.M.P., Snowden M.A., Stubbs R.J., Walton S., Weston H.E. J. Med. Chem. 43:2000;19.
8. Tougou K., Nakamura A., Okuyama Y., Morino A. Drug. Metab. Dispos. 26:1998;355.
9. (a) . For examples, see: Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. Nat. Gen. 14:1996;334 (b) Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A., Furlong C.E. Chem. Biol. Interact. 120:1999;429.
10. (a) . For examples, see: Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. Nat. Gen. 14:1996;334 (b) Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A., Furlong C.E. Chem. Biol. Interact. 120:1999;429.
11. (a) For examples, see: Smolen A., Eckerson H.W., Gan K.N., Hailat N., La Du B.N. Drug. Metab. Dispos. 19:1991;107 (b) Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Br. J. Pharmacol. 112:1997;265.
12. (a) For examples, see: Smolen A., Eckerson H.W., Gan K.N., Hailat N., La Du B.N. Drug. Metab. Dispos. 19:1991;107 (b) Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Br. J. Pharmacol. 112:1997;265.
13. Haley R.W., Billecke S., La Du B.N. Toxicol. Appl. Pharmacol. 1999;227.
14. For reviews and examples, see: (a) Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. J. Clin. Invest. 96:1995;2882 (b) Aviram M. Mol. Med. Today. 5:1999;381 (c) Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Circulation. 101:2000;2510 (d) Durrington P.N., Mackness B., Mackness M.I. Arterioscler. Thromb. Vasc. Biol. 21:2001;473.
15. For reviews and examples, see: (a) Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. J. Clin. Invest. 96:1995;2882 (b) Aviram M. Mol. Med. Today. 5:1999;381 (c) Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Circulation. 101:2000;2510 (d) Durrington P.N., Mackness B., Mackness M.I. Arterioscler. Thromb. Vasc. Biol. 21:2001;473.
16. For reviews and examples, see: (a) Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. J. Clin. Invest. 96:1995;2882 (b) Aviram M. Mol. Med. Today. 5:1999;381 (c) Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Circulation. 101:2000;2510 (d) Durrington P.N., Mackness B., Mackness M.I. Arterioscler. Thromb. Vasc. Biol. 21:2001;473.
17. For reviews and examples, see: (a) Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. J. Clin. Invest. 96:1995;2882 (b) Aviram M. Mol. Med. Today. 5:1999;381 (c) Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Circulation. 101:2000;2510 (d) Durrington P.N., Mackness B., Mackness M.I. Arterioscler. Thromb. Vasc. Biol. 21:2001;473.
18. (a) Ruiz J., Blanche H., James R.W., Garin M.-C.B., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Lancet. 346:1995;869
19. (b) Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. FEBS Lett. 423:1998;57
20. (c) Mackness B., Mackness M.I., Durrington P.N., Arrol S., Evans A.E., McMaster D., Ferrieres J., Ruidavets J.-B., Williams N.R., Howard A.N. Eur. J. Clin. Invest. 30:2000;4
21. (d) Malin R., Jarvinen O., Sisto T., Koivula T., Lehtimaki T. Atherosclerosis. 157:2001;301
22. (e) Gnasso A., Motti C., Irace C., Gennaro D.I., Pujia A., Leto E., Ciamei M., Crivaro A., Bernardini S., Federici G., Cortese C. Atherosclerosis. 164:2002;289.
23. (a) Antikainen M., Murtomaki S., Syvanne M., Pahlman R., Tahvanainen E., Jauhiainen M. J. Clin. Invest. 1996;883
24. (b) Hasselwander O., Savage D.A., McMaster D., Loughrey C.M., McNamee P., Middleton D., Nicholls D.P., Maxwell A.P., Young I.S. Kidney Int. 1999;289
25. (c) Ferre N., Tous M., Paul A., Zamora A., Vendrell J.J., Bardaji A., Camps J., Richart C., Joven J. Clin. Biochem. 35:2002;197.
26. Rodrigo L., Mackness B., Durrington P.N., Hernandez A., Mackness M.I. Biochem. J. 354:2001;1.
27. Billecke S., Draganov D., Counsell R., Stetson P., Watson C., Hsu C., La Du B.N. Drug. Metab. Dispos. 28:2000;1335.
28. Augustinsson K.-B., Ekedahl G. Acta Chem. Scand. 16:1962;240.
29. (a) Nishio E., Watanabe Y. Biochem. Biophys. Res. Com. 236:1997;289
30. (b) Hasselwander O., McMaster D., Fogarty D.G., Maxwell A.P., Nicholls D.P., Young I.S. Clin. Chem. 44:1998;179
31. (c) Sams C., Mason H.J. Hum. Exp. Toxicol. 18:1999;653
32. (d) Aviram M., Dornfeld L., Rosenblat M., Volkova N., Kaplan M., Coleman R., Hayek T., Presser D., Fuhrman B. Am. J. Clin. Nutr. 71:2000;1062. ref 13(b).
33. -1): 3015, 2940, 2907, 2832, 1753, 1594, 1509, 1462, 1298, 1097, 909.
34. 1/2 of the compound. A control tube was also prepared for each compound which did not contain serum.
35. 2 was used and that 200 μL treated serum were assayed in a total volume of 3 mL at 30 °C.
36. Sorenson R.C., Primo-Parmo S.L., Kuo C.-L., Adkins S., Lockridge O., La Du B. Proc. Natl. Acad. Sci. 92:1995;7187.
37. (a) Josse D., Xie W., Renault F., Rochu D., Schopfer L.M., Masson P., Lockridge O. Biochemistry. 38:1999;2816
38. (b) Doorn J.A., Sorenson R.C., Billecke S.S., Hsu C., La Du B.N. Chem. Bio. Interact. 120:1999;235
39. (c) Josse D., Lockridge O., Xie W., Bartels C.F., Schopfer L.M., Masson P. J. Appl. Toxicol. 21:2001;S7.